



3762

Patent

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Lynn et al. Examiner: P. Bianco  
Serial No. : 09/818,486 Group Art Unit: 3762  
Filed : 27 March 2001  
For : Systems and Methods for Collecting Leukocyte-Reduced Blood Components,  
Including Plasma that is Free or Virtually Free of Cellular Blood Species

---

**RESPONSE RE: NOTICE OF ABANDONMENT**

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RECEIVED****MAR 08 2004****TECHNOLOGY CENTER R3700**


Sir:

Applicant has received a Notice of Abandonment in this case, mailed 10 February 2004 (Attachment 1). The Notice states that Applicant failed to respond to the Office Action mailed 31 July 2003.

Applicant mailed an Amendment in response to the Office Action with a certificate of mailing on 2 February 2004 (Attachment 2). The return postcard, date stamped by the Patent Office on 5 February 2004, has acknowledged receipt of this Amendment, and the post card is attached as Attachment 3). Applicant has further submitted a Supplemental response, mailed on 5 February 2004, and received by the PTO on 9 February 2004 (Attachment 4).

Applicant therefore respectfully requests withdrawal of the Notice of Abandonment. Acknowledgment of the active status of this application is respectfully requested.

Respectfully submitted,


By   
Daniel D. Ryan, Reg. No. 29,243

RYAN KROMHOLZ & MANION, S.C.  
PO Box 26618  
Milwaukee, WI 53226  
(262) 783 - 1300  
Customer No. 26308  
26 February 2004  
F-5235 CIP DIV CIP 2/040226 - Withdraw Abandonment



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on 26 February 2004

By  Judith Dunaway

Dated 26 February 2004

RECEIVED  
MAR 08 2004  
TECHNOLOGY CENTER R3700



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/818,486	03/27/2001	Daniel Lynn	F-5235 CIP DIV CIP2	2286

7590 02/10/2004

Michael C. Mayo  
 Baxter Healthcare Corporation  
 Route 120 and Wilson Rd.  
 Round Lake, IL 60073



EXAMINER

BIANCO, PATRICIA

ART UNIT PAPER NUMBER

3762


DATE MAILED: 02/10/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

MAR 08 2004

TECHNOLOGY CENTER R3700



*Booked  
 2-13-04  
 518*

**Notice of Abandonment**

Application No.	Applicant(s)	
09/818,486	LYNN ET AL.	
Examiner	Art Unit	
Patricia M Bianco	3762	

- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -

**RECEIVED**

MAR 08 2004

This application is abandoned in view of:

1. ☒ Applicant's failure to timely file a proper reply to the Office letter mailed on 7/31/03.
  - (a) ☐ A reply was received on \_\_\_\_\_ (with a Certificate of Mailing or Transmission **TECHNOLOGY CENTER R3700**) which is after the expiration of the period for reply (including a total extension of time of \_\_\_\_\_ month(s)) which expired on \_\_\_\_\_.
  - (b) ☐ A proposed reply was received on \_\_\_\_\_, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final rejection. (A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114).
  - (c) ☐ A reply was received on \_\_\_\_\_ but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).
  - (d) ☒ No reply has been received.
2. ☐ Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three months from the mailing date of the Notice of Allowance (PTOL-85).
  - (a) ☐ The issue fee and publication fee, if applicable, was received on \_\_\_\_\_ (with a Certificate of Mailing or Transmission dated \_\_\_\_\_), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Notice of Allowance (PTOL-85).
  - (b) ☐ The submitted fee of \$\_\_\_\_\_ is insufficient. A balance of \$\_\_\_\_\_ is due.  
The issue fee required by 37 CFR 1.18 is \$\_\_\_\_\_. The publication fee, if required by 37 CFR 1.18(d), is \$\_\_\_\_\_.
  - (c) ☐ The issue fee and publication fee, if applicable, has not been received.
3. ☐ Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37).
  - (a) ☐ Proposed corrected drawings were received on \_\_\_\_\_ (with a Certificate of Mailing or Transmission dated \_\_\_\_\_), which is after the expiration of the period for reply.
  - (b) ☐ No corrected drawings have been received.
4. ☐ The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants.
5. ☐ The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.
6. ☐ The decision by the Board of Patent Appeals and Interference rendered on \_\_\_\_\_ and because the period for seeking court review of the decision has expired and there are no allowed claims.
7. ☐ The reason(s) below:

*Patricia M Bianco* 3/7/04  
 Patricia M Bianco  
 Primary Examiner  
 Art Unit: 3762

Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to minimize any negative effects on patent term.